Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
The FDA has approved Pfizer’s biosimilar drug, Retacrit, a cut price competitor Amgen and Johnson & Johnson's bone marrow stimulating drug epoetin alfa. Retacrit (epoetin alfa-epbx), is a biosimilar ...
Hospira, Inc. HSP presented data from two studies on a proposed biosimilar, Retacrit (Epoetin Hospira), at the National Kidney Foundation spring meeting. The drug is a proposed biosimilar to Amgen Inc ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
The Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx), a biosimilar of Epogen/Procrit (epoetin alfa), to treat anemia caused by a number of factors – including undergoing ...
The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback